Eyes On 2027 sets sail next week!
Final boarding call! Eyes On 2027 embarks November 6-7, and there’s still a spot on deck for you. Sign up now for 12 virtual clinical sessions covering the most critical eyecare advances across every specialty. Plus, earn up to 8 COPE-accredited CE hours, ask experts questions live, and enter to win up to $2,000 in raffle prizes!
New Content
The Next Era of Ophthalmology: Why Glaucoma and Cataract Treatment is Reaching an “iPhone Moment"
Rapid-Fire Retina: TKIs, Gene Therapy, and the Durability Race
How I Made CareCredit Simple for My Team and Patients
Dr. Brianna Rhue shares practical ways eyecare practice teams can simplify CareCredit for staff and patients through training, workflows, patient conversations, and performance tracking.
Stabilizing the Tear Film Prior to Cataract Surgery
Sit down with Drs. Preeya K. Gupta and Vance Thompson to review approaches for efficiently addressing tear film instability before cataract surgery.
The First Line of Dry Eye Care—No Prescription Required
Join Drs. Lappin, Quint, Rights, and Zagelbaum to review how to implement first-line therapies for dry eye with OTC drops, nutraceuticals, and lid hygiene.
Topics
The Ocular Surface Burden in Glaucoma: What the Evidence Actually Shows
Beyond Co-Management: A New Growth Model for Optometry Practices
How optometrists are expanding their patient care capabilities through office-based surgery
Roivant, Priovant report positive phase 3 NIU data for brepocitinib
Oral therapy demonstrates broad and significant benefits in adults with NIU; companies target H1 2027 sBLA submission.
Industry payments tied to higher prescribing volume, costs
A Cochrane review links pharmaceutical industry payments and gifts to less appropriate prescribing, higher prescription volumes, and increased medication costs.
FDA approves Xbrane Biopharma's Lucentis biosimilar
Lucamzi (ranibizumab-blrz) is expected to launch in 2027 as the latest intravitreal injection with its reference biologic’s same five retinal indications.
FDA updates recall for CooperVision's Sofmed Breathables Advanced Toric contact lenses
The Next Era of Ophthalmology: Why Glaucoma and Cataract Treatment is Reaching an “iPhone Moment"
As the biopharma industry pursues increasingly complex breakthroughs, some of the most transformative innovations may come not from inventing new categories of medicine, but from reimagining how proven technologies and therapies can work together in scalable, integrated delivery systems. In ophthalmology, that shift has the potential to fundamentally change the management of chronic disease. And it’s happening now, right before our eyes.
2026 Contact Lens Report
Download the free report to learn how optometrists are managing their contact lens practices in 2026!
Rapid-Fire Retina: TKIs, Gene Therapy, and the Durability Race
Join Drs. John Kitchens and David Eichenbaum as they discuss updates in the retina pipeline and what therapies ophthalmologists should keep on their radar.
Clinical Specialties
Stabilizing the Tear Film Prior to Cataract Surgery
The First Line of Dry Eye Care—No Prescription Required
How I Made CareCredit Simple for My Team and Patients
Dr. Brianna Rhue shares practical ways eyecare practice teams can simplify CareCredit for staff and patients through training, workflows, patient conversations, and performance tracking.
The Impact of Presbyopia Drops on Optical Sales
Join Drs. Schaeffer and Chima as they discuss the impact of prescribing presbyopia drops on optical sales and patient care in clinical practice.
Benchmarking Your Contact Lens KPIs: What Top-Performing Practices Are Tracking
This article outlines which contact lens KPIs to track, how your optometry practice compares to industry benchmarks, and where to adjust to increase revenue.
Careers
Beyond the Sales Rep: Understanding Who’s Who in Industry
I Saw It on TV: DTC Pharma Marketing and the New Eyecare Patient
Utilizing AI to Increase Eyecare Practice Efficiency
The Next Era of Ophthalmology: Why Glaucoma and Cataract Treatment is Reaching an “iPhone Moment"
As the biopharma industry pursues increasingly complex breakthroughs, some of the most transformative innovations may come not from inventing new categories of medicine, but from reimagining how proven technologies and therapies can work together in scalable, integrated delivery systems. In ophthalmology, that shift has the potential to fundamentally change the management of chronic disease. And it’s happening now, right before our eyes.
